First Trimester CD93 as a Novel Marker of Preeclampsia and Its Complications: A Pilot Study.

IF 3.1 Q2 PERIPHERAL VASCULAR DISEASE High Blood Pressure & Cardiovascular Prevention Pub Date : 2023-11-01 Epub Date: 2023-11-27 DOI:10.1007/s40292-023-00608-y

Federica Piani, Giovanni Tossetta, Sonia Fantone, Chiara Agostinis, Nicoletta Di Simone, Maurizio Mandalà, Roberta Bulla, Daniela Marzioni, Claudio Borghi

{"title":"First Trimester CD93 as a Novel Marker of Preeclampsia and Its Complications: A Pilot Study.","authors":"Federica Piani, Giovanni Tossetta, Sonia Fantone, Chiara Agostinis, Nicoletta Di Simone, Maurizio Mandalà, Roberta Bulla, Daniela Marzioni, Claudio Borghi","doi":"10.1007/s40292-023-00608-y","DOIUrl":null,"url":null,"abstract":"Introduction: CD93 plays a crucial role in endothelial homeostasis and angiogenesis. Recently its role in hypertension has been investigated, holding promise for novel targeted diagnostic and therapeutic strategies.Aim: We assessed for the first time differences in first trimester serum CD93 levels in women who lately developed preeclampsia (PE) vs. normotensive pregnancy (NP).Methods: First trimester serum CD93 concentrations were assessed in a multicenter cohort of 83 women (34 PE and 49 NP) by ELISA Immunoassay.Results: Serum CD93 was lower in women who developed PE vs. NP (111.8 ± 24.4 vs. 137.5 ± 22.3 ng/ml; p < 0.001). Serum CD93 was associated with a decreased risk of developing PE (OR 0.950, 95% CI 0.922-0.978) and composite neonatal outcome (OR 0.952, CI 0.923-0.982), after adjustment for confounders.Conclusions: PE is accompanied by decreased serum CD93 levels. CD93 might play a role during placentation leading to defective angiogenesis, vascular dysfunction, and PE development.","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"591-594"},"PeriodicalIF":3.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-023-00608-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: CD93 plays a crucial role in endothelial homeostasis and angiogenesis. Recently its role in hypertension has been investigated, holding promise for novel targeted diagnostic and therapeutic strategies.

Aim: We assessed for the first time differences in first trimester serum CD93 levels in women who lately developed preeclampsia (PE) vs. normotensive pregnancy (NP).

Methods: First trimester serum CD93 concentrations were assessed in a multicenter cohort of 83 women (34 PE and 49 NP) by ELISA Immunoassay.

Results: Serum CD93 was lower in women who developed PE vs. NP (111.8 ± 24.4 vs. 137.5 ± 22.3 ng/ml; p < 0.001). Serum CD93 was associated with a decreased risk of developing PE (OR 0.950, 95% CI 0.922-0.978) and composite neonatal outcome (OR 0.952, CI 0.923-0.982), after adjustment for confounders.

Conclusions: PE is accompanied by decreased serum CD93 levels. CD93 might play a role during placentation leading to defective angiogenesis, vascular dysfunction, and PE development.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

妊娠早期CD93作为先兆子痫及其并发症的新标志物:一项初步研究

CD93在内皮稳态和血管生成中起重要作用。最近，它在高血压中的作用已被研究，有望为新的靶向诊断和治疗策略。目的:我们首次评估了最近发生先兆子痫(PE)的妇女与正常妊娠(NP)妇女妊娠早期血清CD93水平的差异。方法:采用ELISA免疫分析法对83名妇女(34名PE和49名NP)孕早期血清CD93浓度进行评估。结果:PE患者血清CD93低于NP患者(111.8±24.4∶137.5±22.3 ng/ml;p结论:PE伴血清CD93水平降低。CD93可能在胎盘形成过程中起作用，导致血管生成缺陷、血管功能障碍和PE发育。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

High Blood Pressure & Cardiovascular Prevention PERIPHERAL VASCULAR DISEASE-

CiteScore

5.70

自引率

3.30%

发文量

期刊介绍： High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited ''State of the Art'' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.